Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roger Stupp

Showing results (301-310 of 314) with videos related to

Pageof 32
Sort By:
Neuro-Oncology|July 19, 2024
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomasKwang-Soo Kim, Karl Habashy, Andrew Gould, et al.
Nature Communications|June 6, 2024
Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomasVíctor A Arrieta, Andrew Gould, Kwang-Soo Kim, et al.
Neuro-Oncology|January 26, 2026
Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneityVictor A Arrieta, J Kada Benotmane, Rebecca Du, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Cancer|February 12, 2022
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Nature Cancer|February 5, 2022
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
Pageof 32

Showing results (301-310 of 314) with videos related to

Sort By:
Pageof 32
Neuro-Oncology|July 19, 2024
Fc-enhanced anti-CTLA-4, anti-PD-1, doxorubicin, and ultrasound-mediated blood-brain barrier opening: A novel combinatorial immunotherapy regimen for gliomasKwang-Soo Kim, Karl Habashy, Andrew Gould, et al.
Nature Communications|June 6, 2024
Ultrasound-mediated delivery of doxorubicin to the brain results in immune modulation and improved responses to PD-1 blockade in gliomasVíctor A Arrieta, Andrew Gould, Kwang-Soo Kim, et al.
Neuro-Oncology|January 26, 2026
Integrated immune profiling of chordomas reveals spatially organized niches and functional heterogeneityVictor A Arrieta, J Kada Benotmane, Rebecca Du, et al.
The Lancet. Oncology|August 29, 2014
Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trialRoger Stupp, Monika E Hegi, Thierry Gorlia, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 2, 2026
Temozolomide Versus Radiotherapy as First-Line Therapy for Low-Grade Glioma: Mature Results of a Randomized Phase III Trial (EORTC 22033-26033/NCIC-CTG/TROG/MRC-CTU)Brigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Lancet (London, England)|August 13, 2017
Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup studyMartin J van den Bent, Brigitta Baumert, Sara C Erridge, et al.
Nature Medicine|July 21, 2025
Author Correction: Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trialFarshad Nassiri, Vikas Patil, Leeor S Yefet, et al.
Nature Cancer|February 12, 2022
Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
The Lancet. Oncology|October 1, 2016
Temozolomide chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3 intergroup studyBrigitta G Baumert, Monika E Hegi, Martin J van den Bent, et al.
Nature Cancer|February 5, 2022
ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastomaVíctor A Arrieta, Andrew X Chen, J Robert Kane, et al.
Pageof 32